Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients presenting with a baseline absolute neutrophil count < 750 cells/mm3 or baseline platelet count < 50000 platelets/mm3 will be categorized as ineligible to receive ganciclovir induction therapy
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is testing foscarnet as a possible treatment for CMV retinitis in AIDS patients who can't take ganciclovir due to myelosuppression or who have not responded to it.
Who is the study for?
This trial is for AIDS patients with CMV retinitis who can't use ganciclovir due to severe side effects like low blood cell counts or because it didn't work for them. They must be able to consent and not have allergies to foscarnet, significant lung/brain issues, or eye conditions that block vision checks.Check my eligibility
What is being tested?
The study tests the safety and effectiveness of a drug called Foscarnet as an initial treatment for CMV retinitis in those where Ganciclovir failed. It also looks at how long the treatment works, its impact on CMV levels in blood/urine, and HIV p24 antigen recovery.See study design
What are the potential side effects?
Foscarnet may cause kidney problems, changes in mineral levels in your blood (like calcium), nausea, seizures if minerals get too low/high, and general discomfort at the injection site.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My neutrophil count is above 750 and my platelet count is above 50,000.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
Astra USALead Sponsor
9 Previous Clinical Trials
311 Total Patients Enrolled
4 Trials studying Cytomegalovirus Retinitis
142 Patients Enrolled for Cytomegalovirus Retinitis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't taken any immune system modifiers or experimental drugs in the last week.I am joining the study because previous treatments with ganciclovir were either harmful or didn't work for me.I do not have allergies to foscarnet, significant lung or brain issues, or eye conditions that prevent eye exams.I am not currently taking Acyclovir or any kidney-damaging medications.I do not have allergies to foscarnet or significant lung, nerve, or eye issues that would prevent an eye exam.I am currently taking Ganciclovir.I have AIDS with CMV retinitis and my previous treatments have failed.My neutrophil count is above 750 and my platelet count is above 50,000.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does the trial protocol allow for people 45 years or older to participate?
"Patients that meet the criteria of this clinical trial must be between 18 and 65 years old. There are 311 studies available for adolescents, while 955 studies have been created accomodate elderly patients."
Answered by AI
Share this study with friends
Copy Link
Messenger